Edward A. Mas II is a member of the Executive Committee and a Shareholder at McAndrews. He is recognized by IAM’s Patent 1000 and Managing Intellectual Property’s IP Stars, and has been described by his clients and peers as a “terrifically savvy litigator” and an “experienced, smart, aggressive, and effective” attorney who “routinely secures the best position for his clients.” In 2025, IAM said “Mas is a highly skilled advocate with a proven track record in high-stakes patent litigation. He specializes in medical devices and biotechnology, demonstrating exceptional expertise and success in these complex fields.”

As a world-class trial and appellate attorney, Ed’s career has included a succession of case victories that have helped define the current terrain of patent law, particularly in the medical device and life sciences fields. He also assists clients with matters related to IP strategy, licensing, portfolio management, clearance opinions, trade secrets, and other areas. He is relentlessly focused on helping clients maximize the value of their intellectual property and protect their investments in research and development.

Ed has served as lead trial counsel in numerous patent infringement suits from coast to coast and has been involved in multi-million-dollar verdicts, awards, and settlements. One of Ed’s professional highlights includes securing a $166 million victory for Advanced Cardiovascular Systems, which rates among the top patent damages awards. In addition, he represents clients in reexaminations and other post-grant proceedings in the United States Patent and Trademark Office.

Ed has successfully briefed and argued appeals before the Federal Circuit, including Wyeth and Cordis Corp. v. Abbott Laboratories. In that case, the Federal Circuit affirmed a finding of patent invalidity for lack of enablement. Similarly, in SciMed Life Systems, Inc. v. ACS, a seminal case on specification estoppel law, the Federal Circuit affirmed a finding of non-infringement. In both matters, sales of the client’s accused products exceeded $1 billion.

Ed works with clients on a wide range of technologies. For example, for more than two decades, he has represented a Fortune 100 global healthcare company in many U.S. and related foreign disputes involving angioplasty equipment, drug-eluting coronary stent systems, diabetes management systems, diagnostic equipment, and nutritional products. Ed also has handled matters involving pharmaceuticals, antibodies and related expression systems, biologics, barcode scanners and printers, bicycle equipment, large industrial equipment, and automotive components, just to name a few.